Prescient Acquires Dolon to Expand Pricing and Market Access Capabilities

Prescient Healthcare Group expanded its commercial consulting platform on March 30 by acquiring Dolon, a London-based specialist in value, pricing, and market access. The deal formally integrates Dolon's practice into Prescient's existing suite of services spanning clinical, commercial, and regulatory strategy for biopharma clients.

Rather than absorbing Dolon wholesale into a single unified unit, Prescient opted to preserve the firm's identity. Dolon will operate as a dedicated practice within the enlarged platform, a structural choice that signals deliberate intent: retaining the specialist culture and client relationships that made Dolon an acquisition target in the first place. That kind of continuity-first integration is increasingly common when consultancies buy narrow, high-value teams where expertise is concentrated in individuals rather than processes.

The strategic logic behind the transaction is straightforward. Prescient already holds capabilities across multiple stages of the drug lifecycle, but pricing and market access represent technically demanding, high-stakes disciplines in biopharma commercialization. Determining how a therapy is valued by payers, priced across markets, and positioned within health technology assessment frameworks requires deep domain knowledge that takes years to build organically. Acquiring Dolon compressed that timeline considerably.

For Prescient's clients, the practical benefit is a more continuous advisory relationship. Previously, a biopharma company might engage separate firms for clinical strategy and then for pricing and reimbursement planning; the combined entity can now support both phases under one relationship. That end-to-end model tends to be stickier and commands higher fees than point-in-time engagements.

The Prescient-Dolon deal also reflects a consolidation pattern running through the biopharma consulting sector more broadly. Platform consultancies have been selectively acquiring specialist firms rather than building capabilities in-house, allowing them to scale advisory depth without the long recruitment cycles that hiring requires. Specialist teams in areas like health economics, regulatory affairs, and market access have become premium targets because their expertise is both scarce and directly tied to client revenue outcomes at the reimbursement and launch stages.

Dolon's London base also adds geographic weight to Prescient's European footprint, relevant given that market access dynamics in the UK and across European payer systems differ substantially from those in the United States. Navigating NICE evaluations, the AMNOG process in Germany, or early access frameworks across EU member states requires country-specific knowledge that cannot easily be replicated from a single headquarters.

The acquisition positions Prescient to pursue more complex, longer-cycle engagements with clients who need strategic continuity from early clinical development through launch and market access negotiations, exactly the kind of high-margin advisory work that justifies premium consulting relationships in biopharma.